Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2695214 | 1.00 | CXCR4 (0.37) | CXCR4NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2694563 | 0.90 | NPC1 (0.35) | CXCR4NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2694567 | 0.90 | NPC1 (0.35) | CXCR4NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2694616 | 0.90 | GCGR (0.35) | CXCR4NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2694610 | 0.90 | GCGR (0.35) | CXCR4NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL2695847 | 0.78 | MEN1 (0.34) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2695843 | 0.78 | MEN1 (0.34) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1206506 | 0.69 | CA12 (0.41) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1792661 | 0.68 | CXCR4 (0.58) | CXCR4NPC1RAB9AHDAC1HDAC6 | |
| SCHEMBL1792659 | 0.68 | CXCR4 (0.58) | CXCR4NPC1RAB9AHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-16 | — | — | US | disclosed |
| US-8168783-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD., (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1961744-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169567-A1 | BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF | CXCR4, CXCL12, CXCR3 | CXCR4 1/4885NPC1 532/4885RAB9A 610/4885 |
| US-20120207765-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR3, CXCR1 | CXCR4 1/4885NPC1 727/4885RAB9A 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.